
NASDAQ:HRMY
This summary was created by AI, based on 2 opinions in the last 12 months.
Harmony Biosciences Holdings Inc (HRMY) continues to draw attention from analysts and stock experts. The company operates in the pharmaceutical industry with a focus on neurological treatments and has been highlighted for its robust development pipeline. Recently, a stop loss was triggered at $33, prompting recommendations to cover the position. Despite some downward movement of 9.5%, experts remain optimistic about the company’s potential, suggesting that it has a significant upside, with a price target of $50.55 indicating a potential increase of 33%. The company’s ongoing positive cash flow and growing reserves further support this bullish outlook.
Harmony Biosciences Holdings Inc is a American stock, trading under the symbol HRMY (previously HRMY-Q on Stockchase) on the NASDAQ (HRMY). It is usually referred to as NASDAQ:HRMY or HRMY
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on HRMY (previously HRMY-Q on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-09-16. Read the latest stock experts ratings for Harmony Biosciences Holdings Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is covered by Stockchase experts and is worth watching.
On 2026-07-24, Harmony Biosciences Holdings Inc (HRMY) stock closed at a price of $35.32.
Our PAST TOP PICK with HRMY has triggered its stop at $33. To remain disciplined, we recommend covering the position at this time.